Noteworthy AACR21 on-demand presentations.
Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions
Five IO areas in early stage development to watch out for at ESMO20
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?
There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?
Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20
Ten intriguing novel agents in early development to watch out for
Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
The December 17, 2010 issue of "Science" has the catchy of title of "Insights of the Decade", one of which is the ubiquitous role of inflammation in multiple chronic illnesses including cancer.
Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma
What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
How the design of different cancer approaches can affect clinical performance
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
New insights emerging from research on cytokines as an effective way to induce anti tumour immunity
What is old is new again - a look at some forgotten oncology targets that are coming back in fashion
Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma
Lessons learned from recent failure and a look at where a few new developments might be coming from...
On launched products, armored CARs and the potential threat from China
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at innate approaches to stimulating the immune system including IL-15 agonists
A look at Nektar's promising IO portfolio and what's next for the up and coming biotech
Final SITC17 Preview and a look at key talks now that the abstracts are available.
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...